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ABSTRACT 
Objective: The psoriatic arthritis (PsA) core domain set for randomized controlled trials (RCTs) and longitudinal 
observational studies (LOS) has recently been updated. The joint counts are central to the measurement of the 
peripheral arthritis component of the musculoskeletal (MSK) disease activity domain. We report the Outcome 
Measures in Rheumatology (OMERACT) 2018 meeting approaches to seek endorsement of the 66/68-swollen and 
tender joint count (SJC66/TJC68) for inclusion in the PsA Core Outcome Measurement Set. 
Methods: Using the OMERACT Filter 2.1 Instrument Selection Process, the SJC66/TJC68 was assessed for (1) 
domain match, (2) feasibility, (3) numerical sense (construct validity), and (4) discrimination (test retest reliability, 
longitudinal construct validity, sensitivity in clinical trials and thresholds of meaning). A protocol was designed to 
assess the measurement properties of the SJC66/TJC68 joint count. The results were summarized in a “Summary of 
Measurement Properties Table” developed by OMERACT. OMERACT members discussed and voted on whether 
the strength of the evidence supported that the SJC66/TJC68 had passed the OMERACT Filter as an outcome 
measurement instrument for the PsA Core Outcome Measurement Set. 
Results: OMERACT delegates endorsed the use of the SJC66/TJC68 for the measurement of the peripheral arthritis 
component of the MSK disease activity domain: Among patient research partners, 100% voted for a “green” 
endorsement, whereas among the group of “other stakeholders”, 85% voted for a “green” endorsement. 
Conclusion: The SJC66/TJC68 is the first fully endorsed outcome measurement instrument using the OMERACT 
Filter 2.1 and the first instrument fully endorsed within the PsA Core Outcome Measurement Set. 
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INTRODUCTION 
Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease that is clinically 
heterogeneous with distinct manifestations including peripheral arthritis, spondylitis, enthesitis, and 
dactylitis, as well as skin and nail features.  Additionally, the disease affects many domains of patients’ 
lives including fatigue, participation, and emotional wellbeing.  The Group for Research and Assessment 
of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) working 
group developed a Core Outcome Set (COS; Figure 1) to specify which key domains should be measured 
in randomized controlled trials (RCTs) and longitudinal observational studies (LOS) for PsA. This was 
endorsed at the 2016 OMERACT meeting.(1, 2)  Since that time, multiple work streams have been 
initiated as part of the Core Outcome Measures for Psoriatic Clinical Trials (COMPACT) study.(3, 4) The 
GRAPPA-OMERACT working group has been evaluating the measurement  properties of multiple 
outcome measurement instruments to develop a PsA Core Outcome Measurement set that would assist 
in standardizing what is measured in RCT’s and how they are measured (Domains and 
Instruments).(5)[omeract instrument selection paper reference to be added]  
 
Among the domains included in the COS, musculoskeletal (MSK) disease activity is considered one of the 
most important for both patients and clinicians.(1) The MSK disease activity domain includes peripheral 
joints, enthesitis, dactylitis, and spine symptoms. The tender and swollen joint counts are central to the 
measurement of the peripheral arthritis element of MSK disease activity. While several joint counts 
exist,(6) there are no existing recommendations about which joint count to use in RCTs or LOS 
measuring peripheral arthritis in PsA, and none have moved through the Instrument Selection Process 
described by OMERACT. 
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The goal of the PsA workshop at OMERACT was to seek endorsement of the 66/68-Swollen and Tender 
Joint Counts (SJC66/TJC68) (Figure 2) as one of the instruments for the PsA Core Outcome Measurement 
Set. In this paper, we describe the instrument selection process as recommended by OMERACT, 
summarize the plenary presentation, and present the voting results and discussion points from the PsA 
workshop and breakout groups at the OMERACT 2018 meeting. 
 
METHODS 
Patient Engagement in the Working Group  
One of the key tenets of the OMERACT process is involving patient research partners (PRPs) in the 
process of developing core outcome sets. In the work presented in this paper, PRPs have been involved 
in all aspects of the project: Three PRPs are part of the GRAPPA-OMERACT working group steering 
committee. They have reviewed and provided feedback on protocols, pre-reading materials, and 
presentations, and helped plan the workshop. Furthermore, PRPs from GRAPPA and OMERACT have 
participated in small groups and were involved in surveys and web-based seminars. 
 
Instrument Selection Process 
Using the OMERACT Filter 2.1 Instrument Selection Process (Figure 3), an instrument is first assessed for 
“Truth: domain match” and “Feasibility” and, if these two steps are met, the instrument may progress to 
the subsequent steps, “Truth 2: Numerical Sense” (i.e., construct validity) and “Discrimination” 
(measured by test retest reliability, longitudinal construct validity, ability to distinguish between 
treatment and placebo groups in clinical trials and thresholds of meaning).(7, 8) To seek endorsement of 
an instrument, the working group assembles the evidence  for the instrument, appraises it and provides 
an overall assessment of the instrument using a “Summary of Measurement Properties” or SOMP table.  
The working group makes a recommendation for endorsement and the attendees then vote if they 
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agree with this recommendation. At least 70% agreement among voting attendees at the session from 
both stakeholder groups (patients AND others) suggests consensus with the working group 
recommendation.  For a more in depth review of the instrument selection process, see the OMERACT 
handbook, Appendix 4.(7) The research protocol was reviewed and approved by the Institutional Review 
Board (IRB) of the University of Pennsylvania (IRB PROTOCOL#: 829776) for the patient research partner 
surveys and webinars, the rest of the project components were deemed exempt from IRB review. 
 
Evaluation of Joint Counts using the OMERACT process 
A systematic literature search (SLR) was first performed to identify instruments that had been used to 
measure peripheral joint activity in PsA and to assess their measurement properties.(9, 10) Primarily the 
SJC28/TJC28, SJC66/TJC68, and SJC76/TJC78 joint counts were identified in the literature.  We addressed 
domain match and feasibility at the GRAPPA meeting in 2017 (Amsterdam) as well as with the working 
group and patient research partners (described in more detail below).  We assessed the measurement 
properties of the joint counts in the literature (and applied the OMERACT Good Methods Checklist to 
assess data quality) and analyzed measurement properties in clinical trial and longitudinal observational 
study datasets (obtained from companies and principal investigators).  The working group requested 
data from phase III trials published between 2010-2017 and was included from 7 phase III RCTs, The 
Tight Control of Inflammation in Psoriatic Arthritis trial and one LOS, the Psoriatic Arthritis Research 
Consortium. A priori, a standardized protocol was designed to address content validity, construct 
validity, responsiveness and discrimination. 
We used this data to complete the summary of measurement properties table and presented 
this to the working group for a final recommendation.  The results were then presented at the 
OMERACT meeting in Terrigal. 
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The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Meeting 
Domain Match and Feasibility of the Joint Counts: Clinicians and other Stakeholders 
Domain match and feasibility for the SJC66/TJC68 were addressed at GRAPPA 2017 in a breakout group 
discussion and, following GRAPPA, among working group members using a web-based survey. During 
the GRAPPA meeting, content validity and feasibility were addressed within a small group with 
clinicians, two patients, and a patient advocate; the voting sheets were completed by 22 people.(11)  
There was consensus (20/22, 91%) among the group that the SJC66/TJC68 was a match for the MSK 
disease activity/peripheral arthritis domain and that there was adequacy of content and no 
redundancies. With regards to feasibility, all the voters agreed that the SJC66/TJC68 was feasible. 
Eighteen working group members completed a follow up online survey. This survey documented 
the reasons for selecting SJC66/TJC68 count over the comparators (28 and 76/78 joint counts).  The 28 
joint count is a core measure for rheumatoid arthritis (RA) and is frequently performed in clinical 
practice.  The 76/78 joint count is performed in some trials. Other joint counts beyond the 28, 66/68, 
and 76/78 (i.e., 32, 44, Ritchie index) were not sufficiently used in RCTs or LOS to merit inclusion.(6) 
Concerns have been raised about these joint counts in PsA: the 28 joint count does not include 
the joints of the feet, and these joints are frequently affected in PsA, this concern was raised by both 
PRPs and clinicians; the 76/78 joint count includes the carpometacarpal (CMC) joints, typically involved 
in osteoarthritis and thus tenderness in this joint is difficult to attribute to PsA, and it separately includes 
the toe PIPs and DIPs, these joints are difficult to decipher individually on exam decreasing feasibility. 
The 28 joint count did not meet domain match and the 76/78 joint count had lower feasibility 
and reduced domain match compared to the SJC66/TJC68.  Given the results of the above discussions 
and surveys with all stakeholders, the working group decided to only move forward the SJC66/TJC68 
through the OMERACT filter (Figure 4). 
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Domain Match and Feasibility of the Joint Counts: Patient Research Partners 
To assess domain match and feasibility from the PRPs perspective, a web-based survey was a designed 
with an embedded video of a clinician (AO) performing the SJC66/TJC68. Respondents were asked to 
note whether they agreed that the SJC66/TJC68 measured their perception of “peripheral arthritis 
disease activity” and whether it was feasible to complete within RCT or LOS visits. PRP representatives of 
GRAPPA and OMERACT were invited to participate in the survey, and fourteen responded. After 
completion of the survey, two web-based seminars were held with the participating PRPs to discuss the 
results by first reporting the survey results and then the discussion was opened for comments, 
questions, or concerns. Points of confusion with the domain were that several patients did not endorse 
for “domain match” because the SJC66/TJC68 did not include the entheses or the spine. AO reminded 
the group that enthesitis and spine symptoms are assessed using separate measures, and this 
explanation was satisfactory to those who voted “no” (although the group did not re-vote as the vote 
was mainly used to start the discussion).  Some patients advocated for inclusion of the CMC joint as a 
common source of pain.  PRPs also noted that the feet and ankles are essential for inclusion in assessing 
peripheral arthritis in PsA. 
Regarding feasibility, all patients felt that the SJC66/TJC68 is feasible however, the only concern 
raised was that when patients are in a lot of pain, getting shoes on and off is uncomfortable and can 
decrease feasibility. Additionally, the patient needs sufficient time to respond during examination (i.e., if 
the SJC66/TJC68is performed too quickly, there will not be sufficient opportunity to say “yes” to a 
tender joint).  It was also noted by several PRPs that for the joint count to be a valid assessment of 
peripheral arthritis, particularly tenderness, there needs to be communication between the physician 
and patient. There was discussion about the fact that the joint examination may miss a joint that was 
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active within the past week but is not active today. Finally, patients felt that there was no clear meaning 
for “tender” and that communication from the physician prior to the joint count is assessed is needed.  
 
Numerical Sense (construct validity) and Discrimination 
We addressed numerical sense and discrimination via an SLR and analysis of RCT datasets. In the SLR, 
1921 unique references were identified, 159 were eligible for full-text article assessment. 87 of these 
were excluded and 72 were included in the good methods analysis (the checklist is applied at the level of 
the instrument and measurement property tested). 59 of the 72 were excluded due to lack of enough 
data regarding the SJC66 and TJC68, and 3 based on the good methods checklist, leaving 10 studies for 
inclusion (Figure 5).  The list of articles and summary of findings was included in Table 1.   The results 
suggest that SJC66 and TJC68 have construct validity. TJC68 has good interrater reliability while SJC66 
has a fair interrater reliability. Regarding responsiveness and discrimination, SJC66 and TJC68 change 
over time in response to treatment (placebo did change as well but less) and the change in SJC66 and 
TJC68 can distinguish between patients receiving an effective therapy compared to placebo.  
 
The working group concluded that the SJC66/TJC68 meets the OMERACT criteria for domain match, 
feasibility, truth and discrimination.  The instruments shortfalls are relatively low inter-rater reliability 
for the SJC only and a lack of studies addressing intra-rater reliability of the TJC/SJC in PsA (Table 1).   
 
OMERACT 2018 PsA Workshop: Plenary Presentation and Breakout Group Discussions 
In the plenary presentation, we presented the evidence that addressed each of the 4 steps of the 
OMERACT Filter 2.1 Instrument Selection Process for SJC66/TJC68.  Data from these studies were 
summarized in the SOMP Table (Table 1).  After the plenary presentation, eight breakout groups were 
asked to discuss the four measurement properties (content validity/domain match, feasibility, construct 
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validity, and discrimination) and vote on agreement with the working group’s assessment of green 
(“good to go”), amber (“some concerns raised”), or red (“not endorsed”). Breakout groups were 
facilitated by one OMERACT-trained facilitator and one reporter; reporters were part of the working 
group or experienced researchers. During breakout groups, the participants had the option to raise 
concerns regarding the working group assessment of “green”.    Overall, most participants agreed with 
our assignment of “green” for content validity/domain match, feasibility, and construct validity. 
Feasibility concerns came up for some groups in that the SJC66/TJC68 takes longer than the reduced 
joint counts, but overall, the majority felt that the SJC66/TJC68 is feasible in the setting of a RCT or LOS.  
In some groups, concerns were raised about discrimination, mainly centered around the insufficient 
data for test-retest reliability and thresholds of meaning (both with only one unpublished study 
available in PsA). Additionally, the concern about the relatively low interrater reliability of the SJC was 
raised. This was countered by the argument that in most RCTs, the assessor is the same throughout the 
study and test-retest reliability, or intrarater reliability, in a single unpublished study was found to be 
quite high (ICC 0.8-0.9) (Tillett et al unpublished). Furthermore, clinicians are generally asked to undergo 
training prior to trial participation to increase interrater reliability.(12) Reasons for endorsement of the 
SJC66/TJC68 that were raised included sending a clear message that this is the preferred joint count 
based upon evidence in order to assist in standardizing joint counts among RCTs. A broader discussion 
was raised during the small groups regarding the meaning of full endorsement of an instrument 
(“green”) or provisional endorsement (“amber). Some wondered whether a ‘green’ instrument would 
then become mandatory, similar to the inner circle of a core domain set.  However, in the PsA 
workshop, “green” was used to denote the sufficient measurement properties to confidently say this is a 
“good” instrument, and “amber” was used to indicate that although this is a good instrument which 
could be used, further research is still required on its measurement properties. It is possible that 
multiple instruments for the same domain will pass through the filter at a “green” level, thus requiring a 
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subsequent consensus process to identify the best instrument. Additional discussion then turned to 
define what is good enough? We assigned an “amber” to test-retest reliability and thresholds of 
meaning because of only one unpublished study for each.  The OMERACT handbook suggests that the 
instrument should then be amber.  However, the working group felt that the instrument (SJC66/TJC68) 
should be endorsed as ‘green’ given the data in all other domains collectively being excellent; the 
studies evaluating test-retest reliability and thresholds of meaning being sufficient; and further research 
on these domains, though supportive, are not critical to further inform the preferred use of the 
SJC66/TJC68 over other joint counts.  
 
Vote for the 66/68 Joint Counts 
Following report back from the groups and discussion, we held a vote for the endorsement of the 
instrument. Among PRPs, 100% (of 14 patient votes in total) voted for a “green” endorsement.  Among 
all other stakeholders, 88% (84 of 96 votes in total) voted for a “green” endorsement.   
 
Summary 
Through the years, the lack of standardization of the instruments to measure peripheral arthritis in PsA 
has resulted in the use of different instruments to assess peripheral arthritis in RCTs and LOS.  
After a careful assessment by PRPs, clinicians, methodologists, representatives of the pharmaceutical 
industry and other stakeholders, and in accordance with the OMERACT filter 2.1, the evidence 
supporting the measurement properties of the SJC66/TJC68 was assessed and resulted in full 
endorsement (“green”) by OMERACT as an instrument to measure MSK disease activity/peripheral 
arthritis in PsA. The SJC66/TJC68 is the first “green” instrument to enter the PsA Core Outcome 
Measurement Set. 
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The MSK disease activity domain includes the heterogeneous disease manifestations of PsA: enthesitis, 
dactylitis, spondylitis/axial arthritis and peripheral arthritis. An ongoing program will assess and 
eventually seek endorsement of the optimal instruments that measure the other components of the 
MSK disease activity domain. In the meantime, PRPs, regulatory agencies, investigators developing 
protocols for RCTs and LOS, and other stakeholders can be confident with the SJC66/TJC68 and its 
adoption of the SJC66/TJC68 will be monitored in published RCTs and LOS. 
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TABLE AND FIGURE LEGENDS 
Table 1: Summary of Measurement Properties Table for TJC68/SJC66 
The color indicates the good methods checklist/recommendation; the +/- sign indicates the adequacy of 
the data in support of the instrument. 
For test-retest reliability, we have provided primary data for test-retest reliability (1 study) but also 
additional evidence to support the test-retest (intra-rater) reliability of the joint count in RA (2 studies). 
A hand search for test-retest reliability in RA was conducted after identifying the gap in test-retest 
reliability in PsA so as to provide additional context about this property in the assessment of peripheral 
arthritis. 
Some studies were excluded because the measurement properties tested did not meet the the good 
methods checklist: Gladman et al.1990 (13) (test-retest reliability, necessary summary statistics not 
provided), Englebrecht et al. 2010 (14) (construct validity, only tested correlation among subsets of TJC 
68 and SJC66), Schoels et al. 2010 (15) (construct validity and longitudinal construct validity, didn’t test 
associations of interest between joint counts and other individual measures) 
 
Figure 1 Updated 2016 PsA Core Domain Set.  
Final set of core domains to be measured in randomized clinical trials and longitudinal observational 
studies, endorsed by OMERACT in 2016. 
*MSK disease activity includes peripheral joints, enthesitis, dactylitis, and spine symptoms 
Abbreviations: MSK = musculoskeletal 
 
Figure 2 The SJC66/TJC68 Joint Count 
66 swollen and 68 tender joints are assessed (the hips are not assessed for swelling). The joint count is 
scored as a sum of the tender joints and a sum of the swollen joints.   
16 
 
 
Figure 3: OMERACT instrument selection process 
Selecting an instrument the OMERACT way means proceeding through the steps shown in the figure: 
first defining the domain to be measured, identifying candidate instruments, assessing whether the 
instruments match the domain and feasibility, narrowing the list (removing instruments that do not 
match the domain), gathering evidence about measurement properties in a systematic literature search 
and data analysis, identifying the winners, and taking to OMERACT for endorsement.   This figure was 
designed by Dorcas Beaton, OMERACT Handbook. 
 
Figure 4 The OMERACT Filter 2.1 Instrument Selection Process for the of the 66/68-Swollen and 
Tender Joint Counts (SJC66/TJC68). 
*Discrimination includes longitudinal construct validity, clinical trial discrimination (green circles), test-
retest reliability and thresholds of meaning (amber circles). 
Abbreviations: JC 28=28/28 Swollen and Tender Joint Counts; SJC76/TJC78=76/78-Swollen and Tender 
Joint Counts   
 
Figure 5 PRISMA diagram 
We conducted a systematic literature review for all four components of “MSK Disease Activity” which 
includes peripheral arthritis, enthesitis, dactylitis, and spine symptoms.  In the current report, we 
focused on the TJC68 and SJC66 and thus many manuscripts went through the good methods checklist 
but only 10 met criteria and applied to the joint counts. Abbreviations: SLR=Systematic Literature 
Review; SJC66 = 66 Swollen Joint Count; TJC78 = 68 Tender Joint Count.   
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